Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Leap Therapeutics Presents Trx518 Data At Esmo Immuno-oncology Congress 2018 And Updated Data From Dkn-01 Study In Biliary Tract Cancer
Family Office

Leap Therapeutics Presents Trx518 Data At Esmo Immuno-oncology Congress 2018 And Updated Data From Dkn-01 Study In Biliary Tract Cancer

by prnewswire.com posted 4months ago 134 views
CAMBRIDGE, Mass., Dec. 14, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented clinical data from its ongoing Phase I/II study of TRX518 in combination with gemcitabine, KeytrudaÒ (pembrolizumab), or OpdivoÒ (nivolumab) in patients with advanced solid tumors at the...

In this article